

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	To Be Accorded
Filing Date	02/11/2004
First Named Inventor	Michel PAIRET
Art Unit	1617
Examiner Name	Mojdeh BAHAR
Attorney Docket Number	1/1174-1-C1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/CH/		US- 5,610,163	03/11/1997	Banholzer, R. et al	
/CH/		US- 4,042,700	08/16/1977	Banholzer, R. et al	
/CH/		US- 4,608,377	08/26/1986	Banholzer, R. et al	
/CH/		US- 4,783,534	11/08/1988	Banholzer, R. et al	
/CH/		US- 5,654,314	08/05/1997	Banholzer, R. et al	
/CH/		US- 5,770,738	06/23/1998	Banholzer, R. et al	
/CH/		US- 5,952,505	09/14/1999	Banholzer, R. et al	
/CH/		US- 6,486,321	11/26/2002	Banholzer, R. et al	
/CH/		US- 6,506,900	01/14/2003	Banholzer, R. et al	
/CH/		US- 2003/0018019	01/23/2003	Meade, C. J. M. et al	
/CH/		US- 2002/0137764	09/26/2002	Drechsel, K. et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/CH/		WO 01/78736 A1	10/25/2001	Glaxo Group Ltd.		
/CH/		WO 01/78739 A1	10/25/2001	Glaxo Group Ltd.		
/CH/		WO 01/78741 A1	10/25/2001	Glaxo Group Ltd.		
/CH/		WO 01/78743 A1	10/25/2001	Glaxo Group Ltd.		
/CH/		EP 05040112 A2	05/03/1992	Ciba-Geigy AG		

Examiner
Signature

/Carlic Huynh/

Date
Considered

09/19/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Compleat if Known	
				Application Number	To Be Accorded
				Filing Date	02/11/2004
				First Named Inventor	Michel PAIRET
				Art Unit	1617
				Examiner Name	Mojdeh BAHAR
				Attorney Docket Number	1/1174-1-C1
Sheet	2	of	3		

[illegible][illegible]

Examiner Signature	/Carlic Huynh/	Date Considered	09/19/2007
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IDS
2/11/04

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	To Be Accorded		
		Filing Date	02/11/2004		
		First Named Inventor	Michel PAIRET		
		Art Unit	1617		
		Examiner Name	Mojdeh BAHAR		
Sheet	3	of	3	Attorney Docket Number	1/1174-1-C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/CH/		F. MON, et al; Aerosol Therapy in Asthma, Revue Des Maladies Respiratoires, Bd. 6, Nr. 3, 1989 Seiten 189-200 - XP001078722	
/CH/		G. BLAZANO, et al, Effectiveness and Acceptability of a Domiciliary Multidrug Inhalation Treatment in Elderly Patients with Chronic Airflow Obstruction: Metered Dose Inhaler Versus Jet Nebulizer, Journal of Aerosol Medicine, Vol. 13, No. 1, 2000, PP 25-33	
/CH/		RUTGERS, STEVEN R., et al; Short-term Treatment with Budesonide Does Not Improve Hyperresponsiveness to Adenosine 5- Monophosphate in COPD, American Journal of Respiratory and Critical Care Medicine, Vol. 157, pp 880-887	
/CH/		CONSTANT P. van SCHAYCK, et al; Periodic Treatment Regimens with Inhaled Steroids in Asthma or Chronic Obstructive Pulmonary Disease, Journal of American Medical Association, July 12, 1995, Vol. 274, No. 2, pp 161-164	
/CH/		DEMETRI PAVIA, et al; Preliminary Data from Phase II Studies with Respimat, a Propellant-Free Soft Mist Inhaler, Journal of Aerosol Medicine, Vol. 12, Supplement 1, 1999 pp S-33-S-39	
/CH/		KOICHI NISHIMURA, et al; Additive effect of oxitropium bromide in combination with inhaled corticosteroids in the treatment of elderly patients with chronic asthma, Allergology International (1999) 48: 85-88. Short Communication XP-001070756	
/CH/		NISHIMURA, ET AL; "Additive effect of oxitropium bromide in combination with inhaled corticosteroids in the treatment of elderly patients with chronic asthma"; Allergology International, 3/1999, pgs 85-88	
/CH/		GENNARO, ET AL; Ed., Remington's Pharmaceutical Sciences, 18th Ed., 1990, Pgs 1694-1699, 1706-1707, 1709	

Examiner Signature	/Carlic Huynh/	Date Considered	09/19/2007
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.